BRISTOL-MYERS SQUIBB COMPANY
BMY · Healthcare · $136.1B mkt cap · FY2025 filings · · Shallow moat ·
Doesn't clear the bar
The five investor questions
2021–2025 (latest 5 aligned FYs; v3 window cap 5): revenue $46.4B to $48.2B, increasing; diluted EPS 3.12 to 3.46, increasing.
Median gross margin 71.8% over 10y, very stable.
Not enough years of ROIC data to score returns on capital.
Net debt/EBITDA 2.3x, interest coverage 6x.
Owner earnings changed +9.1%/yr over up to the ten most recent annual observations.
The returnsOnCapital component abstained: Not enough years of ROIC data to score returns on capital. The other four 20% weights were renormalized over the scored 80%.
Price vs. value if growth stopped today
A cautious baseline, not a price target: what the shares may support if normalized owner earnings simply hold steady.
- $15.5B
- $84.49
- $84.49
- $66.86
- 21% below value if growth stopped today
A discount this large is often a warning rather than a bargain — the market may expect earnings to keep falling. See the revenue trend above.
How to read this
What today’s price assumes: owner earnings shrinking ~5%/yr over 5 years. The estimate assumes owner earnings stay flat (0% growth).
We solve for the constant annual change in owner earnings that would make the five-year zero-growth estimate equal today’s price. This keeps the existing model inputs and calculation unchanged; it is an expectations lens, not a forecast.
This zero-growth estimate assumes trailing owner earnings persist — unreliable for declining businesses. The recent FY revenue series does not trigger the three-consecutive-declines flag.
Among the current top-score group, the median current price is 238% above the zero-growth estimate across 49 of the current top 50 companies by Moat Score with both values.
Score records captured Sep 4, 2026.
Exactly which 50 companies?
FTNT, META, MEDP, IBEX, MSFT, GOOG, LULU, ANF, IDXX, TXRH, FHI, QLYS, FFIV, ADBE, LLY, MANH, VEEV, RMD, GRMN, PCTY, EAT, UI, SSD, MNST, DOCS, LRCX, MCO, CPRT, NTAP, NVDA, CORT, SFM, MPTI, ULTA, SN, ROL, CTAS, PAYC, IRMD, INTU, DECK, MORN, JKHY, TPR, LGCY, DAL, GWW, ISRG, MPWR, LOPE
Missing a usable price or zero-growth estimate: ANF.
Model details under moat-index@3.0.0: zero-growth multiple 11.1×, capped-growth comparison at no more than 18×; 9% discount rate; high-end growth 0% (capped at 4%) using min(5y revenue CAGR, 5y diluted-EPS CAGR), clamped to 0%–4%; maintenance capex uses min(capex, D&A); abstain when D&A is unavailable. This is a disclosed model range, not intrinsic value as fact.
20 years of fundamentals
The business, in plain English
BRISTOL-MYERS SQUIBB COMPANY booked $48.2B of revenue in FY2025 in the Healthcare sector and kept 71.1% of it as gross profit — a high-margin business by that measure. After every other cost, 14.6% of each revenue dollar reached the bottom line.
Across the filed record, revenue grew from $15.6B (FY2007) to $48.2B (FY2025) — about 6.5% a year compounded over 18 years.
The balance sheet carried $45.1B of total debt in FY2025 against $9.8B of owner earnings — roughly 4.6 years of owner earnings to retire it all. Balance-Sheet Safety scores it 33/100.
This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.
Exact FY and FY-1 financing invested-capital inputs are required.. Current-year EBIT, tax expense, and non-zero pretax income are required for standard ROIC.
Exact FY and FY-1 financing invested-capital inputs are required.. Current-year EBIT, tax expense, and non-zero pretax income are required for standard ROIC.
The explained ROIC gaps have filed inputs but no meaningful positive invested-capital denominator. Other gaps mean the item is not in the filings for that year. The series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.
Visual explainers
The filing-backed explainer service is temporarily unavailable, so no partial or guessed chart is shown.
Moat Score history
Tier changesSame-methodology and same-normalizer crossings of the Wide / Narrow / Shallow bars
- Normalizer upgraded unstamped (version unknown)tomoat-xbrl-normalizer@1.1.0 — readings across versions aren’t comparedJul 26, 2026
- Methodology upgraded moat-index@2.0.0tomoat-index@3.0.0 — readings across versions aren’t comparedJul 23, 2026
- Methodology upgraded moat-index@1.2.0tomoat-index@2.0.0 — readings across versions aren’t comparedJul 20, 2026
Scores are logged append-only and never overwritten — this record cannot be reconstructed retroactively, which is exactly why it’s worth keeping.
Insider activity
Form 4 reports mix P/S market or private transactions with compensation-plan mechanics. Activity casually described as “insider selling” can include compensation mechanics; awards, tax withholding, and option exercises are shown by their exact filed class here, never collapsed into “Bought” or “Sold.”
These are disclosed filing facts and arithmetic aggregates, not a signal or verdict.
The insider-filing service is temporarily unavailable, so no partial or guessed answer is shown for BMY.
Healthcare context
#111 of 708 scored Healthcare companies, ranked by Moat Score.
Nearest peers by Moat Score
- #109PTCT PTC Therapeutics, Inc.59.8 out of 100, Shallow moatShallow moat
- #110PGNY Progyny, Inc.59.7 out of 100, Shallow moatShallow moat
- #112RIGL RIGEL PHARMACEUTICALS, INC.59.5 out of 100, Shallow moatShallow moat
- #113HTFL Heartflow, Inc.59.4 out of 100, Shallow moatShallow moat
Compare BMY with its nearest peers →All Healthcare companies on the Index →
Common questions about BMY
- Does BRISTOL-MYERS SQUIBB COMPANY have an economic moat?
- Based on its FY2025 SEC filings, the Moat Index scores BRISTOL-MYERS SQUIBB COMPANY (BMY) 59.6 out of 100 — a Shallow moat. The five questions behind that score begin at 20% each; if exactly one genuinely lacks data, the other four weights are renormalized and disclosed. revenue and EPS trend 57, pricing power 98, returns on capital not measurable from the filings, balance-sheet safety 33, capital allocation 50.
- Is BMY trading below the conservative owner-earnings estimate?
- The value if growth stopped today — a zero-growth baseline — is $84.49 per share. It capitalizes normalized owner earnings at a 9% rate and assumes 0% growth. Versus a recent price of $66.86, that is 21% below value if growth stopped today. The model also publishes a capped-growth comparison, but the zero-growth estimate is the cautious baseline. It assumes trailing owner earnings persist and is unreliable for declining businesses. This is an educational estimate from primary SEC filings, not intrinsic value as a fact or investment advice.
- How has BMY's Moat Score changed over time?
- The record logs 17 readings since Jul 17, 2026; the latest reads 59.6 out of 100 (shallow moat). No tier changes on record yet. (Methodology or normalizer upgrades on Jul 20, 2026, Jul 23, 2026, Jul 26, 2026 re-based the score; readings across versions aren't compared.) The history is append-only — readings are only ever added, never rewritten.